anti-CD20 agents

Anti-CD20 agents are a class of biologic drugs, specifically monoclonal antibodies (mAbs), that target the CD20 surface antigen expressed on the surface of pre-B and mature B lymphocytes. Binding to CD20 leads to the depletion of B cells through several immunological mechanisms, including antibody-dependent cell-mediated cytotoxicity (ADCC), complement-dependent cytotoxicity (CDC), and the direct induction of apoptosis. This class is categorized into generations: first-generation chimeric antibodies (e.g., rituximab), second-generation humanized or fully human antibodies (e.g., ocrelizumab, ofatumumab), and third-generation glycoengineered antibodies (e.g., obinutuzumab) designed for enhanced effector function. These agents are cornerstone therapies for B-cell malignancies, such as non-Hodgkin lymphoma and chronic lymphocytic leukemia, and are increasingly utilized in autoimmune and inflammatory conditions, including multiple sclerosis and rheumatoid arthritis.

Other names

anti-CD20 monoclonal antibodiesanti-CD-20 monoclonal antibodiesanti-CD 20 monoclonal antibodiesCD20 inhibitorsCD-20 inhibitorsCD 20 inhibitorsCD20-directed antibodiesCD-20-directed antibodiesCD 20-directed antibodiesanti-CD20 mAbsanti-CD-20 mAbsanti-CD 20 mAbs